Anzalone Christopher Richard's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Dec 23, 2025
- Accession no.
- 0001423029-25-000007
- Filed
- Dec 23, 2025
- Trade date
- Dec 19-22, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions. Open-market sales total $1.77M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anzalone Christopher RichardCIK 0001423029 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | Common Stock | SSaleDisposed | −3,979 | $66.67 | −$265,279.93 | 3,827,978 | Direct | |
| Dec 19, 2025 | Common Stock | SSaleDisposed | −8,147 | $68.01 | −$554,077.47 | 3,819,831 | Direct | |
| Dec 19, 2025 | Common Stock | SSaleDisposed | −1,319 | $68.48 | −$90,325.12 | 3,818,512 | Direct | |
| Dec 22, 2025 | Common Stock | SSaleDisposed | −10,012 | $68.33 | −$684,119.96 | 3,808,500 | Direct | |
| Dec 22, 2025 | Common Stock | SSaleDisposed | −2,574 | $68.85 | −$177,219.9 | 3,805,926 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.